| abstract |
FIELD: medicine.SUBSTANCE: invention relates to medicine. Disclosed are methods and use of CETP inhibitor, namely, dalcetrapib, for treating a subject with acute coronary syndrome, where the subject has nucleotide polymorphisms in the gene of adenylate cyclase type 9 (ADCY9) in chromosome 16. There are also presented methods and applications of dalcetrapib in the preparation of a drug for treating a subject with acute coronary syndrome and for reducing the risk of a cardiovascular event.EFFECT: subject genotyping according to the present invention can find further application in treating cardiovascular diseases and in predicting response to such treatment.30 cl, 8 dwg, 8 tbl, 1 ex |